When was NATURWOHL PHARMA (YOKEBE) acquired by PERRIGO COMPANY?

NATURWOHL PHARMA (YOKEBE) was acquired by PERRIGO COMPANY in 2015.

What was the revenue of NATURWOHL PHARMA (YOKEBE) at the time of the deal?

The revenue of NATURWOHL PHARMA (YOKEBE) at the time of the deal is estimated to be in the range of 25M - 50M EUR.

How is the data for the NATURWOHL PHARMA (YOKEBE) acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NATURWOHL PHARMA (YOKEBE) deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://investor.perrigo.com/2015-07-22-Perrigo-To-Acquire-Leading-German-Dietary-Supplement-Brand-Yokebe

← DATABASE

Home Database Healthcare & PharmaNATURWOHL PHARMA (YOKEBE)

07/2015

NATURWOHL PHARMA (YOKEBE) acquired by PERRIGO COMPANY

GERMANY Life Sciences / Pharma & Biotech / Generics / Labs REV 25M - 50M EUR

Context

The acquisition of Naturwohl by Perrigo marks a major categorical advancement for the organization’s European self-care division. The strategic logic of this transaction hinges on a "category-entry" maneuver, merging the target’s technical operational depth in the weight management and dietary supplement space with the acquirer’s established pan-European distribution network and the commercial infrastructure of Omega Pharma. This structural alignment provides the combined entity with the marketing hardware and scientific talent necessary to address the increasing consumer demand for preventative health and nutritional optimization.

NATURWOHL PHARMA (YOKEBE), which reported an EBITDA margin of in 2015, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.9x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Naturwohl Pharma GmbH is a German company of specialized health and wellness solutions. The organization operates primarily within the "meal replacement" category, prioritizing a technical product architecture based on shake and liquid formulations designed for metabolic optimization. Rather than following a generic nutritional model, the firm utilizes a science-led approach to dietary supplementation, providing a value proposition centered on quality, efficacy, and consumer trust. Its strategy is anchored in market share dominance within the German-speaking pharmacy and retail channels, acting as a primary partner for consumers seeking self-managed health improvements.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2015

2014

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
02/2016	ASTORG / GOLDMAN SACHS	HRA PHARMA	FRANCE	Generics / Labs
02/2016	TE CONNECTIVITY	CREGANNA MEDICAL	Ireland	Medical Devices
06/2015	BC PARTNERS	PHARMATHEN	GREECE	CDMO
11/2014	QUALIUM	IMV TECHNOLOGIES	FRANCE	R&D Biotech
11/2014	PERRIGO COMPANY	OMEGA PHARMA	BELGIUM	Generics / Labs
09/2014	INSTITUT MERIEUX / SAGARD / SOFIPROTEOL	CEVA SANTE ANIMALE	FRANCE	Animal Health
02/2014	MONTAGU PRIVATE EQUITY	NEMERA	FRANCE	Medical Consumables
01/2014	FIVE ARROWS	DUTSCHER	FRANCE	Medical Consumables
10/2013	ARDIAN	LABORATOIRES ANIOS	FRANCE	Medical Consumables
07/2013	CHARTERHOUSE	DOC GENERICI	ITALY	Generics / Labs

REFERENCES

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NATURWOHL PHARMA (YOKEBE) by PERRIGO COMPANY are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.